Calvet David, Touzé Emmanuel, Mas Jean-Louis
Service de Neurologie, Hôpital Sainte-Anne et Université Paris V René Descartes.
Presse Med. 2006 Apr;35(4 Pt 2):679-82. doi: 10.1016/s0755-4982(06)74662-0.
Antiplatelet therapy is the reference treatment for secondary prevention after noncardioembolic ischemic stroke. The main aim of the Match study was to compare the combination of aspirin (75 mg) and clopidogrel (75 mg) with clopidogrel (75 mg) alone in secondary prevention after recent ischemic stroke or transcient ischemic attack in high-risk patients. The incidence of the composite principal endpoint (ischemic stroke, myocardial infarction, vascular death, or acute ischemic event causing hospitalization) was 15.7% at 18 months in patients in the aspirin-clopidogrel arm, compared with 16.7% in the placebo-clopidogrel arm. The relative risk reduction (6.4%) was not significant (95%CI, -4.6 to 16.3; p=0.244). Patients receiving the combination of aspirin and clopidogrel had more life-threatening bleeding than those treated by clopidogrel alone (2.6% vs 1.3%; 95%CI, 1.3 to 2.6; p<0.001). Recruitment that began too late and an over-selected population, with overrepresentation of patients with diabetes and small vessel disease in particular, may partly explain these negative results.
